Roivant Sciences Ltd. $ROIV Shares Bought by First Turn Management LLC

First Turn Management LLC grew its stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 23.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,186,817 shares of the company’s stock after purchasing an additional 227,114 shares during the quarter. Roivant Sciences makes up about 2.9% of First Turn Management LLC’s holdings, making the stock its 17th biggest position. First Turn Management LLC’s holdings in Roivant Sciences were worth $25,754,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Morgan Stanley raised its holdings in Roivant Sciences by 31.7% during the fourth quarter. Morgan Stanley now owns 58,359,553 shares of the company’s stock worth $1,266,402,000 after purchasing an additional 14,036,696 shares in the last quarter. Vanguard Group Inc. raised its holdings in Roivant Sciences by 8.4% during the fourth quarter. Vanguard Group Inc. now owns 42,059,041 shares of the company’s stock worth $912,681,000 after purchasing an additional 3,254,113 shares in the last quarter. Rubric Capital Management LP raised its holdings in Roivant Sciences by 14.7% during the second quarter. Rubric Capital Management LP now owns 20,370,336 shares of the company’s stock worth $229,574,000 after purchasing an additional 2,603,260 shares in the last quarter. State Street Corp raised its holdings in Roivant Sciences by 4.8% during the second quarter. State Street Corp now owns 19,773,480 shares of the company’s stock worth $222,847,000 after purchasing an additional 911,827 shares in the last quarter. Finally, UBS Group AG increased its holdings in shares of Roivant Sciences by 570.0% in the 4th quarter. UBS Group AG now owns 18,390,792 shares of the company’s stock valued at $399,080,000 after acquiring an additional 15,645,836 shares during the period. Institutional investors and hedge funds own 64.76% of the company’s stock.

Roivant Sciences Price Performance

Shares of Roivant Sciences stock opened at $30.04 on Friday. The firm’s fifty day simple moving average is $28.95 and its 200-day simple moving average is $25.98. The stock has a market capitalization of $21.61 billion, a price-to-earnings ratio of -50.07 and a beta of 1.13. Roivant Sciences Ltd. has a 12 month low of $10.70 and a 12 month high of $32.79.

Roivant Sciences (NASDAQ:ROIV) last announced its earnings results on Wednesday, May 20th. The company reported $0.28 EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.57. The business had revenue of $2.52 million for the quarter, compared to analysts’ expectations of $3.41 million. Roivant Sciences had a negative net margin of 3,629.19% and a negative return on equity of 20.54%. During the same period in the previous year, the company posted ($0.29) EPS. Analysts anticipate that Roivant Sciences Ltd. will post -1.83 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ROIV has been the topic of a number of recent research reports. TD Cowen lifted their target price on shares of Roivant Sciences from $38.00 to $41.00 and gave the company a “buy” rating in a report on Thursday, May 21st. Leerink Partners set a $42.00 target price on shares of Roivant Sciences in a report on Thursday, May 21st. Weiss Ratings cut shares of Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, May 22nd. HC Wainwright reaffirmed a “buy” rating and issued a $34.00 target price on shares of Roivant Sciences in a report on Thursday, May 21st. Finally, Piper Sandler reaffirmed an “overweight” rating on shares of Roivant Sciences in a report on Thursday, May 21st. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $33.59.

Insider Activity

In other Roivant Sciences news, CEO Eric Venker sold 200,000 shares of the business’s stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $30.27, for a total value of $6,054,000.00. Following the transaction, the chief executive officer directly owned 1,613,063 shares of the company’s stock, valued at approximately $48,827,417.01. The trade was a 11.03% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CAO Jennifer Humes sold 13,538 shares of the business’s stock in a transaction on Wednesday, April 8th. The shares were sold at an average price of $28.37, for a total transaction of $384,073.06. Following the completion of the transaction, the chief accounting officer directly owned 84,191 shares in the company, valued at $2,388,498.67. This represents a 13.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 945,173 shares of company stock valued at $27,654,456. 10.80% of the stock is owned by corporate insiders.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.